|
May 9
|
Q1 2024 Editas Medicine Inc Earnings Call
|
|
May 8
|
Bristol-Myers Squibb Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
|
|
May 7
|
A Look at Pharma ETFs Post Q1 Earnings
|
|
May 6
|
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
|
|
May 6
|
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
|
|
May 6
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
|
|
May 6
|
Uncover the Potential: 3 Discounted Stocks Ready for a Comeback
|
|
May 4
|
Bristol-Myers Squibb (NYSE:BMY) shareholders have endured a 33% loss from investing in the stock a year ago
|
|
May 3
|
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
|
|
May 3
|
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
|
|
May 3
|
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
|
|
May 2
|
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
|
|
May 1
|
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
|
|
Apr 30
|
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
|
|
Apr 30
|
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Apr 29
|
J&J, Bristol Myers lose challenges to US drug price negotiation program
|
|
Apr 29
|
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
|
|
Apr 29
|
Repertoire pivot pays dividends with Bristol Myers deal
|
|
Apr 27
|
Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Apr 26
|
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
|